Sichuan Biokin Pharmaceutical Co. Ltd. A (688506): Gewinn- und Verlustrechnung
| Preis (11.09.2026) | 52W Hoch | 52W Tief |
| 238,62 Renminbi Yuan | 404 Renminbi Yuan | 200,1 Renminbi Yuan |
| Analysten Konsens | Buy | Outperform | Hold | Underperform | Sell |
| 336,12 Renminbi Yuan | - | - | - | - | - |
| #Shares | Short [%] | Short Ratio |
| 412.873.817 | - | - |
Kennzahl in 1000 CNY | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
Umsatz | 2.520.113,323 | 5.822.717,804 | 561.870,733 | 703.281,559 | 796.731,824 |
Herstellungskosten | 232.398,812 | 264.385,235 | 229.283,46 | 232.737,903 | 197.725,104 |
Bruttoergebnis | 2.287.714,511 | 5.558.332,569 | 332.587,274 | 470.543,656 | 599.006,72 |
▸ Brutto-Marge | 90,78% | 95,46% | 59,19% | 66,91% | 75,18% |
Betriebliche Aufwendungen | 3.031.076,727 | 1.814.673,283 | 1.074.813,902 | 723.492,134 | 692.284,918 |
Operativer Gewinn/Verlust | -743.362,216 | 3.743.659,286 | -742.226,628 | -252.948,479 | -93.278,198 |
▸ Operative Marge | -29,5% | 64,29% | -132,1% | -35,97% | -11,71% |
Zinsen (Netto) | 141.265,633 | 163.564,166 | -18.975,607 | -21.714,281 | -8.217,274 |
▸ Zinsausgaben | 85.069,303 | 42.523,199 | 24.678,818 | 22.480,879 | 8.692,101 |
▸ Zinseinnahmen | 226.334,936 | 206.087,365 | 5.703,212 | 766,597 | 474,827 |
Andere Ausgaben | 119.336,777 | -70.930,176 | 7.810,739 | 14.410,998 | 2.941,207 |
Gewinn vor Steuern | -721.433,36 | 3.978.153,627 | -769.012,974 | -289.073,758 | -104.436,678 |
Steueraufwand | - | - | - | - | - |
Minderheitenanteil | 332.184,494 | 270.649,071 | 11.485,911 | -6.694,672 | -4.445,381 |
Nettogewinn/-verlust | -1.053.617,854 | 3.707.504,556 | -780.498,885 | -282.379,086 | -99.991,298 |
▸ Netto-Marge | -41,81% | 63,67% | -138,91% | -40,15% | -12,55% |
Kennzahlen dieser Seite im Lexikon
Weitere Informationen findest du im Takani-Lexikon.